U.S. Markets closed


YHD - YHD Delayed Price. Currency in USD
Add to watchlist
- (-)
At close: 06:07PM EDT
Full screen
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (5Y Monthly)N/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • PR Newswire

    Sobi publishes 2021 Annual and Sustainability Report

    Swedish Orphan Biovitrum AB (publ) (Sobi®) has released the company's 2021 Annual and Sustainability Report. The integrated report summarises business and strategy, financial performance and work on sustainability.

  • PR Newswire

    Sobi to cease ReFacto manufacturing in the first quarter of 2024

    Sobi® today announced that its contract with Pfizer for the manufacture of drug substance for ReFacto AF®/Xyntha® (ReFacto) has been amended due to clarity of final order volumes and will now expire in the first quarter of 2024, earlier than the previous expiry date at the end of 2025. Manufacturing of drug substance for ReFacto will be transferred to Pfizer's production unit in Ireland, ensuring continued patient access.

  • PR Newswire

    Gamifant approved in China for the treatment of primary haemophagocytic lymphohistiocytosis

    Sobi® today announced that the National Medical Products Administration of China (NMPA) has approved Gamifant® (emapalumab) for use in China. The indication is for treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. The approval followed the recommendation announced in February 2022.